Search > Pneumonia
90 Participants NeededMy employer runs this trial

agenT-797 for Pneumonia

Recruiting at 3 trial locations
MT
Overseen ByMiNK Therapeutics Clinical Trial Information
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: MiNK Therapeutics
Disqualifiers: Pregnancy, Breastfeeding, Cytokine release syndrome, others
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).

Are You a Good Fit for This Trial?

This trial is for adults hospitalized with severe pneumonia who are having trouble getting enough oxygen (moderate to severe respiratory failure). Participants must be receiving standard treatments for their condition.

Inclusion Criteria

I have sudden, severe trouble getting enough oxygen.
I have moderate to severe acute respiratory distress syndrome (ARDS).
I developed severe pneumonia with serious breathing problems within the last 7 days.
See 1 more

Exclusion Criteria

More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent
Pregnancy or breastfeeding
Current participation in another interventional clinical trial, or receipt of an investigational medicinal product within 30 days prior to screening, unless reviewed and approved in writing by the medical monitor
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Run-in Phase

Participants receive open-label agenT-797 plus standard of care to characterize the baseline population

2 weeks

Phase 2

Participants are randomized to receive either agenT-797 plus SOC or placebo plus SOC in a double-blinded manner

2 weeks
Visits on Day 3, Day 7, Day 14

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Trial Overview

The study compares a single IV dose of agenT-797 plus standard care versus placebo plus standard care, to see if it helps reduce short-term death rates in people with severe pneumonia and serious breathing problems.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: agenT-797 plus SOCExperimental Treatment2 Interventions
Group II: Placebo plus SOCPlacebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

MiNK Therapeutics

Lead Sponsor

Trials
3
Recruited
70+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.